- Previous Close
1.8500 - Open
1.8970 - Bid 1.8750 x --
- Ask 1.9450 x --
- Day's Range
1.8500 - 1.8970 - 52 Week Range
1.6200 - 2.4600 - Volume
66,568 - Avg. Volume
21,903 - Market Cap (intraday)
102.606M - Beta (5Y Monthly) 0.48
- PE Ratio (TTM)
11.56 - EPS (TTM)
0.1600 - Earnings Date Feb 24, 2025
- Forward Dividend & Yield 0.10 (5.41%)
- Ex-Dividend Date Mar 21, 2025
- 1y Target Est
--
Vita Life Sciences Limited, a healthcare company, engages in formulating, packaging, distributing, and selling vitamins and supplements in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, and China. The company also offers various minerals, herbs, and superfoods. In addition, it provides products for therapeutic areas, such as nervous system; nutritionals; urinary health; weight management; immunity; skin, hair, and nails; liver and digestion; fertility, pregnancy, and postpartum; blood sugar management; cardiovascular health; pain and inflammation; men, women, and children's health; antioxidants; bones, joints, and muscles; and eye health. The company markets its products through pharmacies and health food channels under the Herbs of Gold, VitaHealth, and VitaScience brands. Vita Life Sciences Limited was founded in 1947 and is headquartered in Kirrawee, Australia.
vitalifesciences.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: VLS.AX
View MorePerformance Overview: VLS.AX
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VLS.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VLS.AX
View MoreValuation Measures
Market Cap
102.61M
Enterprise Value
74.52M
Trailing P/E
11.72
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.29
Price/Book (mrq)
1.96
Enterprise Value/Revenue
0.94
Enterprise Value/EBITDA
5.54
Financial Highlights
Profitability and Income Statement
Profit Margin
11.05%
Return on Assets (ttm)
11.06%
Return on Equity (ttm)
18.36%
Revenue (ttm)
79.5M
Net Income Avi to Common (ttm)
8.78M
Diluted EPS (ttm)
0.1600
Balance Sheet and Cash Flow
Total Cash (mrq)
28.6M
Total Debt/Equity (mrq)
0.99%
Levered Free Cash Flow (ttm)
4.43M